EUVIMEDEUVIMED entdecken
Crossref

Colesterolo-LDL e oltre: quali target e con quali terapie

Paolo Magni

Il Diabete · 07.05.2026 · 38 (1)

DOI: 10.30682/ildia2601c ↗

Kurz gefasst

Fachartikel in der Zeitschrift Il Diabete, online erschienen am 07.05.2026. Verfasst von Paolo Magni.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerotic cardiovascular disease is the leading cause of mortality, morbidity, and disability, and the presence of diabetes mellitus increases its progression and severity. SCORE2 charts are used for risk stratification in Europe. Circulating LDL cholesterol levels remain the primary reference biomarker and should be maintained within specific targets based on the severity of the risk. Current pharmacological therapy today offers a wide range of drugs that can be combined individually for optimal efficacy and safety.

Zitieren

APA

Magni, P. (2026). Colesterolo-LDL e oltre: quali target e con quali terapie. Il Diabete, 38(1). https://doi.org/10.30682/ildia2601c

Vancouver

Magni P. Colesterolo-LDL e oltre: quali target e con quali terapie. Il Diabete. 2026;38(1). doi:10.30682/ildia2601c

BibTeX
@article{Magni2026,
  author = {Magni, Paolo},
  title = {Colesterolo-LDL e oltre: quali target e con quali terapie},
  journal = {Il Diabete},
  year = {2026},
  volume = {38},
  number = {1},
  doi = {10.30682/ildia2601c}
}
Kostenlos starten →